Trichomonas vaginalis infection linked to more than two-fold increase in the risk of prostate carcinoma


A study from Harvard School of Public Health and Brigham and Women's Hospital researchers has found a strong association between the common sexually transmitted infection, Trichomonas vaginalis, and risk of advanced and lethal prostate carcinoma in men.

The study is published in the Journal of the National Cancer Institute ( JNCI ).

Prostate cancer is the most common cancer among men in western countries, and the second leading cause of cancer-specific mortality. Identifying modifiable risk factors for the lethal form of prostate cancer offers the greatest opportunity to reduce suffering from this disease.

One potential risk factor is inflammation, which appears to play an important role in the development and progression of prostate cancer, but the source of inflammation of the prostate is not clear. Trichomonas vaginalis, which infects an estimated 174 million people globally each year and is the most common non-viral sexually transmitted infection, can infect the prostate and could be a source of inflammation. With respect to prostate cancer prevention, it is noteworthy that up to three-quarters of men infected with Trichomonas vaginalis may not realize they are infected, since they may not have any symptoms.

A previous study had found an association between risk of prostate cancer and Trichomonas vaginalis infection, but was not large enough to determine if there was a link between the infection and advanced and lethal disease.

In the present study, the researchers analyzed blood samples from 673 men with prostate cancer who were participants in the Physicians' Health Study and compared infection status based on antibody levels to 673 control subjects who were not diagnosed with prostate cancer. The blood samples were collected in 1982, on average a decade before cancer diagnosis.

The results showed that Trichomonas vaginalis infection was associated with a more than two-fold increase in the risk of prostate cancer that was advanced stage at diagnosis, and a nearly three-fold increase in prostate cancer that would result in death. ( Xagena )

Source: Harvard School of Public Health, 2009

XagenaMedicine_2009



Link: Xapedia - Medical Encyclopedia